NEDD9 and hepatocellular carcinoma: Additionally, miR-509-3p and platelet-derived growth factor receptor alpha (PDGFRA), which are targets of LINC00467, promoted proliferation and invasion, repressed apoptosis, and ameliorated the resistance to axitinib, the commonly-used drug for HCC (Chan et al., 2017; Li W. et al., 2021) Moreover, Zheng et al. described that silencing LINC00467 could modulate HCC cell growth and development by targeting the miR-18a-5p/NEDD9 axis.